Sort
10,766 grants matching “checkpoint inhibitor”
A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy
$214,399Wantong Yao · University Of Tx Md Anderson Can Ctr · R21 · FY2024 · CA
Preclinical Development of Therapeutics in Murine Models of Lung Cancer
$214,340Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Ciprofloxacin enhances DNA repair capacity after radiation combined injury
$214,310Juliann Gong Kiang · Henry M. Jackson Fdn For The Adv Mil/Med · R21 · FY2008 · AI
Molecular Modulator of RPA and RAD51 in Maintaining Genome Stability
$214,232Weihang Chai · Loyola University Chicago · R01 · FY2023 · CA
Novel mouse models using MADR-GESTALT technology to accelerate glioma research
$214,029Linda M Liau · University Of California Los Angeles · P50 · FY2021 · CA
Project 2 - Joshua Hood, PhD
$213,996Joshua L. Hood · University Of Louisville · P20 · FY2022 · GM
The role of gut microbe-derived choline metabolites in driving the pro-inflammatory macrophage phenotype and restricting pancreatic cancer
$213,733Rahul Suresh Shinde · Wistar Institute · R21 · FY2022 · CA
Cancer Hijacks Enzyme Substrate Mutations to Facilitate Tumorigenesis
$213,727Pengda Liu · Univ Of North Carolina Chapel Hill · R21 · FY2023 · CA
Bcl-2 Proteins in Mechanism of Anti-mitotic Drug Action
$213,574Timothy C Chambers · Univ Of Arkansas For Med Scis · R01 · FY2013 · CA
WEE1 inhibition and tumor immunity
$213,256Bin Zhang · Northwestern University At Chicago · R01 · FY2020 · CA
Extracellular Vesicle Core
$213,200Sicheng Wen · Rhode Island Hospital · P30 · FY2023 · GM
RAPAMYCIN BLOCKADE OF PROTEIN PHOSPHATASE SIGNALING
$213,076David L. Brautigan · University Of Virginia · R01 · FY2007 · CA
Role of ATM in Cardiac Myocyte Loss and Myocardial Remodeling
$213,000Krishna Singh · East Tennessee State University · R21 · FY2008 · HL
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to Immunotherapy
$212,878Jeffrey J. Ishizuka · Yale University · K08 · FY2024 · CA
INTERACTION OF YEAST CHECKPOINT PROTEINS AS DRUG ASSAY
$212,856University Of North Texas Hlth Sci Ctr · R01 · FY2003 · CA
(PQC1) PLK1 And EPHX3 Promotion Of Genomic Instability In Bronchial Dysplasia
$212,834Daniel Thomas Merrick · University Of Colorado Denver · R21 · FY2014 · CA
Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy
$212,696Hyungsoo Kim · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2022 · CA
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
$212,669Randy F. Sweis · University Of Chicago · K08 · FY2021 · CA
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
$212,669Randy F. Sweis · University Of Chicago · K08 · FY2019 · CA
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
$212,669Randy F. Sweis · University Of Chicago · K08 · FY2018 · CA
Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
$212,669Randy F. Sweis · University Of Chicago · K08 · FY2020 · CA
RADIATION INDUCED G1 CHECKPOINT ARREST IN YEAST
$212,664University Of Chicago · R01 · FY2003 · GM
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer
$212,659David B. Solit · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy
$212,579Shana O Kelley · University Of Toronto · R01 · FY2021 · CA
Targeting Liver-X-Receptor Regulation of Prostate Cancer Immune-Evasion
$212,479Colin Ashton Flaveny · Saint Louis University · R21 · FY2020 · CA